Particle Therapy Market (Therapy: Proton Therapy and Heavy Ion Therapy; Service: Cyclotrons, Synchrotrons, and Synchrocyclotrons) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
Companies Mentioned
Varian Medical Systems, Inc.
Sumitomo Heavy Industries, Ltd.
Provision Healthcare
Protom International, Inc.
Optivus Proton Therapy, Inc.
Mevion Medical Systems, Inc.
IBA Worldwide
Hitachi, Ltd.
Danfysik A/S
Advanced Oncotherapy plc
Countries
North America
Europe
Asia Pacific
Rest of the World
Forecast Year (first) - 2022
Forecast Year (last) - 2031
Forecast Year ( first) Value - 560.3
Forecast Year (last) Value - 1267.16
CAGR % - 0.086
Currency - US$ Mn
- 1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Particle Therapy Market
- 4. Market Overview
- 4.1. Introduction
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Particle Therapy Market Analysis and Forecast, 2017–2031
- 4.4.1. Market Revenue Projections (US$ Mn)
- 5. Key Insights
- 5.1. Technological Advancements
- 5.2. Reimbursement Scenario
- 5.3. Particle Therapy Facilities In Clinical Operation, 2021
- 5.4. Average Prices, by Region, 2021
- 5.5. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)
- 6. Global Particle Therapy Market Analysis and Forecast, By Therapy
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Therapy, 2017–2031
- 6.3.1. Proton Therapy
- 6.3.2. Heavy Ion Therapy (carbon therapy, He, pion)
- 6.4. Market Attractiveness Analysis, By Therapy
- 7. Global Particle Therapy Market Analysis and Forecast, By Application
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by Application, 2017–2031
- 7.3.1. Pediatric Cancer
- 7.3.2. Lung Cancer
- 7.3.3. Bladder Cancer
- 7.3.4. Brain & Spinal Cord Tumors (BSCT)
- 7.3.5. Breast Cancer
- 7.3.6. Gastrointestinal (GI) Cancers
- 7.3.7. Hepatocellular Carcinoma (HCC)
- 7.3.8. Head & Neck Cancers (HNC)
- 7.3.9. Others
- 7.4. Market Attractiveness Analysis, By Application
- 8. Global Particle Therapy Market Analysis and Forecast, By Service
- 8.1. Introduction & Definition
- 8.2. Key Findings / Developments
- 8.3. Market Value Forecast, by Service, 2017–2031
- 8.3.1. Cyclotrons
- 8.3.2. Synchrotrons
- 8.3.3. Synchrocyclotrons
- 8.4. Market Attractiveness Analysis, By Service
- 9. Global Particle Therapy Market Analysis and Forecast, By End-user
- 9.1. Introduction & Definition
- 9.2. Key Findings / Developments
- 9.3. Market Value Forecast, by End-user, 2017–2031
- 9.3.1. Hospitals
- 9.3.2. Academic & Research Centers
- 9.4. Market Attractiveness Analysis, By End-user
- 10. Global Particle Therapy Market Analysis and Forecast, By Region
- 10.1. Key Findings
- 10.2. Market Value Forecast, by Region
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Rest of the World
- 10.3. Market Attractiveness Analysis, By Region
- 11. North America Particle Therapy Market Analysis and Forecast
- 11.1. Introduction
- 11.1.1. Key Findings
- 11.2. Market Value Forecast, by Therapy, 2017–2031
- 11.2.1. Proton Therapy
- 11.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
- 11.3. Market Value Forecast, by Application, 2017–2031
- 11.3.1. Pediatric Cancer
- 11.3.2. Lung Cancer
- 11.3.3. Bladder Cancer
- 11.3.4. Brain & Spinal Cord Tumors (BSCT)
- 11.3.5. Breast Cancer
- 11.3.6. Gastrointestinal (GI) Cancers
- 11.3.7. Hepatocellular Carcinoma (HCC)
- 11.3.8. Head & Neck Cancers (HNC)
- 11.3.9. Others
- 11.4. Market Value Forecast, by Service, 2017–2031
- 11.4.1. Cyclotrons
- 11.4.2. Synchrotrons
- 11.4.3. Synchrocyclotrons
- 11.5. Market Value Forecast, by End-user, 2017–2031
- 11.5.1. Hospitals
- 11.5.2. Academic & Research Centers
- 11.6. Market Value Forecast, by Country, 2017–2031
- 11.6.1. U.S.
- 11.6.2. Canada
- 11.7. Market Attractiveness Analysis
- 11.7.1. By Therapy
- 11.7.2. By Application
- 11.7.3. By Service
- 11.7.4. By End-user
- 11.7.5. By Country
- 12. Europe Particle Therapy Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Market Value Forecast, by Therapy, 2017–2031
- 12.2.1. Proton Therapy
- 12.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
- 12.3. Market Value Forecast, by Application, 2017–2031
- 12.3.1. Pediatric Cancer
- 12.3.2. Lung Cancer
- 12.3.3. Bladder Cancer
- 12.3.4. Brain & Spinal Cord Tumors (BSCT)
- 12.3.5. Breast Cancer
- 12.3.6. Gastrointestinal (GI) Cancers
- 12.3.7. Hepatocellular Carcinoma (HCC)
- 12.3.8. Head & Neck Cancers (HNC)
- 12.3.9. Others
- 12.4. Market Value Forecast, by Service, 2017–2031
- 12.4.1. Cyclotrons
- 12.4.2. Synchrotrons
- 12.4.3. Synchrocyclotrons
- 12.5. Market Value Forecast, by End-user, 2017–2031
- 12.5.1. Hospitals
- 12.5.2. Academic & Research Centers
- 12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
- 12.6.4. Spain
- 12.6.5. Italy
- 12.6.6. Rest of Europe
- 12.7. Market Attractiveness Analysis
- 12.7.1. By Therapy
- 12.7.2. By Application
- 12.7.3. By Service
- 12.7.4. By End-user
- 12.7.5. By Country/Sub-region
- 13. Asia Pacific Particle Therapy Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Market Value Forecast, by Therapy, 2017–2031
- 13.2.1. Proton Therapy
- 13.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
- 13.3. Market Value Forecast, by Application, 2017–2031
- 13.3.1. Pediatric Cancer
- 13.3.2. Lung Cancer
- 13.3.3. Bladder Cancer
- 13.3.4. Brain & Spinal Cord Tumors (BSCT)
- 13.3.5. Breast Cancer
- 13.3.6. Gastrointestinal (GI) Cancers
- 13.3.7. Hepatocellular Carcinoma (HCC)
- 13.3.8. Head & Neck Cancers (HNC)
- 13.3.9. Others
- 13.4. Market Value Forecast, by Service, 2017–2031
- 13.4.1. Cyclotrons
- 13.4.2. Synchrotrons
- 13.4.3. Synchrocyclotrons
- 13.5. Market Value Forecast, by End-user, 2017–2031
- 13.5.1. Hospitals
- 13.5.2. Academic & Research Centers
- 13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
- 13.6.1. China
- 13.6.2. Japan
- 13.6.3. India
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
- 13.7. Market Attractiveness Analysis
- 13.7.1. By Therapy
- 13.7.2. By Application
- 13.7.3. By Service
- 13.7.4. By End-user
- 13.7.5. By Country/Sub-region
- 14. Rest of the World Particle Therapy Market Analysis and Forecast
- 14.1. Introduction
- 14.1.1. Key Findings
- 14.2. Market Value Forecast, by Therapy, 2017–2031
- 14.2.1. Proton Therapy
- 14.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
- 14.3. Market Value Forecast, by Application, 2017–2031
- 14.3.1. Pediatric Cancer
- 14.3.2. Lung Cancer
- 14.3.3. Bladder Cancer
- 14.3.4. Brain & Spinal Cord Tumors (BSCT)
- 14.3.5. Breast Cancer
- 14.3.6. Gastrointestinal (GI) Cancers
- 14.3.7. Hepatocellular Carcinoma (HCC)
- 14.3.8. Head & Neck Cancers (HNC)
- 14.3.9. Others
- 14.4. Market Value Forecast, by Service, 2017–2031
- 14.4.1. Cyclotrons
- 14.4.2. Synchrotrons
- 14.4.3. Synchrocyclotrons
- 14.5. Market Value Forecast, by End-user, 2017–2031
- 14.5.1. Hospitals
- 14.5.2. Academic & Research Centers
- 14.6. Market Attractiveness Analysis
- 14.6.1. By Therapy
- 14.6.2. By Application
- 14.6.3. By Service
- 14.6.4. By End-user
- 15. Competition Landscape
- 15.1. Market Player - Competition Matrix (by tier and size of companies)
- 15.2. Market Share Analysis, by Company, 2020
- 15.3. Company Profiles
- 15.3.1. Advanced Oncotherapy plc
- 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.1.2. Product Portfolio
- 15.3.1.3. SWOT Analysis
- 15.3.1.4. Strategic Overview
- 15.3.2. Danfysik A/S
- 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.2.2. Product Portfolio
- 15.3.2.3. SWOT Analysis
- 15.3.2.4. Strategic Overview
- 15.3.3. Hitachi, Ltd.
- 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.3.2. Product Portfolio
- 15.3.3.3. SWOT Analysis
- 15.3.3.4. Strategic Overview
- 15.3.4. IBA Worldwide
- 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.4.2. Product Portfolio
- 15.3.4.3. SWOT Analysis
- 15.3.4.4. Strategic Overview
- 15.3.5. Mevion Medical Systems, Inc.
- 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.5.2. Product Portfolio
- 15.3.5.3. SWOT Analysis
- 15.3.5.4. Strategic Overview
- 15.3.6. Optivus Proton Therapy, Inc.
- 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.6.2. Product Portfolio
- 15.3.6.3. SWOT Analysis
- 15.3.6.4. Strategic Overview
- 15.3.7. Protom International, Inc.
- 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.7.2. Product Portfolio
- 15.3.7.3. SWOT Analysis
- 15.3.7.4. Strategic Overview
- 15.3.8. Provision Healthcare
- 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.8.2. Product Portfolio
- 15.3.8.3. SWOT Analysis
- 15.3.8.4. Strategic Overview
- 15.3.9. Sumitomo Heavy Industries, Ltd.
- 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.9.2. Product Portfolio
- 15.3.9.3. SWOT Analysis
- 15.3.9.4. Strategic Overview
- 15.3.10. Varian Medical Systems, Inc.
- 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.10.2. Product Portfolio
- 15.3.10.3. SWOT Analysis
- 15.3.10.4. Strategic Overview
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook